• news.cision.com/
  • ChemoTech/
  • Scandinavian ChemoTech participates in the physical signing and conducts training at the newly initiated Centre of Excellence "CoE" in India

Scandinavian ChemoTech participates in the physical signing and conducts training at the newly initiated Centre of Excellence "CoE" in India

Report this content

The Company's CEO Mohan Frick attended the physical signing ceremony and thus the official start of the Centre of Excellence collaboration, which has been initiated at India Sweden Healthcare Innovation Centre at AIIMS Jodhpur. The first TSE training treatments for breast, head and neck cancer were also performed.

Mohan Frick, our international application specialist Gayathri Iyer and representatives from Business Sweden were present during the signing ceremony. Yesterday, the Company’s applications specialist completed the training and certification of five doctors within the fields of surgery, medical oncology and radiology at AIIMS Jodhpur. These are the first doctors to be certified in TSE at a State hospital in India.

The patients, who were treated during the training, suffered from cancer where the assessment had been made that standard of care will not be beneficial. This now marks the start of the CoE that is expected to initiate its first studies with the aim of establishing clinical data for the effect of TSE treatment. The treatments performed were not part of any study.

“It has been a long process and both the Company and the doctors have been looking forward to reaching this goal for a while. Although it may now take a long time to get the go-ahead from the Ethics Committee, it feels as if we have already reached an important milestone today which in the long run can create completely new opportunities for TSE and the patients we will treat.” - says Mohan Frick, CEO of ChemoTech

“We are happy to initiate the collaboration with the training on Tumour Specific Electroporation that is conducted this week. We are looking forward to conduct clinical research to evaluate the impact of this technology on the patient outcomes after it gets all the required clearances from the Ethical Committee.”- says Dr. Sanjeev Misra, Director, AIIMS Jodhpur

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00


Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: certifiedadviser@penser.se

India-Sweden Healthcare Innovation Centre
The India-Sweden Healthcare Innovation Centre is a tripartite collaboration between AIIMS Delhi, AIIMS Jodhpur and Swedish Trade Commissioner’s office (Business Sweden) and knowledge partners AstraZeneca, NASSCOM and Vision Zero Cancer. The collaboration is envisioned to develop an ecosystem of open innovation by identifying problem statements of mutual interest which the healthcare delivery stakeholders can use to collaborate and address current and future challenges in the healthcare sector in India & Sweden. This platform enables collaboration through development of Centres of Excellences, Skilling, and Capacity Building and by also working with Start-ups toward Scaleup of solutions for affordable and accessible healthcare in line with the objectives of the Government of India. For more information, please visit: www.indiaswedenic.com

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.